UnknownPhase 1NCT04796675

Cord Blood Derived Anti-CD19 CAR-Engineered NK Cells for B Lymphoid Malignancies

Studying Acute lymphoblastic leukemia

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Principal Investigator
Yu Hu
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Intervention
Fludarabine + Cyclophosphamide + CAR-NK-CD19 Cells(drug)
Enrollment
27 enrolled
Eligibility
18 years · All sexes
Timeline
20212024

Study locations (1)

Collaborators

Shanghai Simnova Biotechnology Co.,Ltd.

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04796675 on ClinicalTrials.gov

Other trials for Acute lymphoblastic leukemia

Additional recruiting or active studies for the same condition.

See all trials for Acute lymphoblastic leukemia

← Back to all trials